What's Happening?
Morrison Foerster has announced the addition of Kathleen Kean as a partner in its Boston office, specifically within the life sciences transactions and licensing and technology transactions groups. Kean brings over 20 years of experience in private practice
and in-house roles, advising biotechnology, pharmaceutical, diagnostics, and medical device companies. Her expertise includes complex licensing, commercialization, and multibillion-dollar collaboration and M&A-adjacent transactions. Kean's role will involve counseling clients on licensing arrangements, collaboration agreements, and various corporate transactions. She joins Morrison Foerster from Goodwin, enhancing the firm's capabilities in the life sciences sector.
Why It's Important?
Kathleen Kean's appointment is significant for Morrison Foerster as it strengthens the firm's presence in the competitive life sciences market. Her extensive experience in high-stakes transactions and strategic advisory roles will be an asset to the firm's clients, particularly in navigating complex licensing and commercialization challenges. This move reflects Morrison Foerster's commitment to expanding its expertise and influence in the biotechnology and pharmaceutical industries, which are critical sectors for innovation and economic growth. Kean's addition is likely to enhance the firm's ability to attract and retain high-profile clients seeking specialized legal counsel.
